Exploring novel lead scaffolds for SGLT2 inhibitors: Insights from machine learning and molecular dynamics simulations.
從機器學習和分子動力學模擬中探索 SGLT2 抑制劑的新型引物骨架。
Int J Biol Macromol 2024-03-27
An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits.
一種GLP-1R/GIPR共激動劑肽的不平衡形式，具有特定位置的N端PEG化，以最大化代謝益處。
iScience 2024-03-22
In-silico screening and identification of glycomimetic as potential human sodium-glucose co-transporter 2 inhibitor.
潛在的人類鈉葡萄糖共轉運輸蛋白2抑制劑的「體外篩選和醣類類似物的識別」。
Comput Biol Chem 2024-04-28
Customizable Click Biochemistry Strategy for the Design and Preparation of Glucagon-like Peptide-1 Conjugates and Coagonists.
設計和製備類胰高血糖素-1共軛物和共激素的可定制點擊生物化學策略。
Bioconjug Chem 2024-05-15
Poly(allylamine)-adorned heptylcarboxymethyl galactomannan nanocarriers of canagliflozin for controlling type-II diabetes: Optimization by Box-Behnken design and in vivo performance.
聚(丙烯胺)修飾的七碳羧甲基半乳甘露聚糖納米載體用於控制 II 型糖尿病的 canagliflozin：通過 Box-Behnken 設計的優化及體內表現。
Int J Biol Macromol 2024-07-31
Transforming canagliflozin solubility using lipidic carrier and its pharmacokinetic study.
使用脂質載體改變 canagliflozin 的溶解度及其藥物動力學研究。
Pharm Dev Technol 2024-12-05
Design, synthesis and biological evaluation of non-glucosidal based 1,3,4-thiadiazoles as SGLT-2 inhibitors.
非葡萄糖苷基 1,3,4-噻二唑作為 SGLT-2 抑制劑的設計、合成及生物評估。
Future Med Chem 2025-02-12
Convenient Synthesis of β-C-acyl Glycosides and its Application in the Synthesis of Scleropentaside A, Scleropentaside B and the Derivatives of Dapagliflozin.
β-C-酰基糖苷的便捷合成及其在 Scleropentaside A、Scleropentaside B 及 Dapagliflozin 衍生物合成中的應用。
Chemistry 2025-02-21
Kinetic Steering of Amyloid Formation and Polymorphism by Canagliflozin, a Type-2 Diabetes Drug.
Canagliflozin 對於淀粉樣蛋白形成和多形性的動力學引導。
J Am Chem Soc 2025-02-22